- About Us
- Research & Pipeline
- Investor Centre
- Media Centre
Our CEO, Dr James Garner sat down with Peter Switzer to discuss Kazia’s upcoming value-driving milestones in 2020 and the development of lead program, paxalisib, for Switzer Financial Group’s The CEO Masterclass series.
Our CEO, Dr James Garner sat down with Boardroom Media to discuss Kazia joining the GBM AGILE international phase II / III study in glioblastoma with its lead program, GDC-0084.
Our Chief Executive Officer, Dr James Garner, sat down with Stuart Roberts of Pitt Street Research in Sydney to discuss the company’s recent announcement of positive interim efficacy data from its phase II trial of GDC-0084 in glioblastoma.
Our CEO, Dr James Garner, sat down with CommSec’s Tom Piotrowski recently to discuss the company’s recent $4 million capital raising as well as key data readouts from Kazia’s clinical trials.
Our Chief Executive Officer, Dr James Garner, sat down with Karen Tan from Proactive Investors in Sydney to discuss the company’s recent achievements and upcoming milestones.
Kazia has been named as a winner in the 2019 Australian and New Zealand Leadership Forum (ANZLF) Trans-Tasman Innovation & Growth Awards.
Our CEO, Dr James Garner recently presented an overview of the company as a guest speaker at the 2019 Gold Coast Investment Showcase.
Enter your email address to subscribe to our insights and receive notifications of new posts by email.
Required values are marked